Max Health and Orion Pharma are proud to announce the launch of STALEVO® (levodopa, carbidopa and entacapone) tablets in New Zealand. Stalevo is a pioneering triple therapy for Parkinson’s and is fully funded from 1 February 2025.
STALEVO combines levodopa, carbidopa, and entacapone in a single tablet, providing a convenient solution for patients not stabilised on traditional levodopa/dopa decarboxylase inhibitor treatment.
Stalevo details are as follows:
Stalevo levodopa/carbidopa/entacapone OneLink Code Pharmacode
Stalevo 50/12.5/200 1260191 2696533
Stalevo 100/25/200 1260192 2696541
Stalevo 150/37.5/200 1260193 2696568
Stalevo 200/50/200 1260194 2696576
As with all other Max Health products, Stalevo Tablets can be ordered from Onelink using this contact information.
Phone: 0800-70-80-60
Fax: 0800-26-69-60
Email: customerservices@onelink.co.nz
